Erdheim–Chester Disease With Multiorgan Involvement, Following Polycythemia Vera
暂无分享,去创建一个
C. Doglioni | G. Cavalli | L. Dagna | P. Bianchi | A. Cortelezzi | U. Gianelli | A. Iurlo | N. Orofino | D. Cattaneo
[1] S. Verstovsek,et al. Polycythemia vera and essential thrombocythemia , 2018 .
[2] J. Snowden,et al. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours , 2015, British Journal of Cancer.
[3] A. Tomelleri,et al. Erdheim-Chester disease. , 2015, European journal of internal medicine.
[4] M. Ferrarini,et al. Cardiovascular manifestations of Erdheim-Chester disease. , 2015, Clinical and experimental rheumatology.
[5] P. Grenier,et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Barbui,et al. CME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management , 2015 .
[7] M. Griesshammer,et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. , 2015, The New England journal of medicine.
[8] O. Abdel-Wahab,et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. , 2014, Blood.
[9] K. Chang,et al. Erdheim-Chester disease with rare radiological features in a 14-year old girl with pre-B Acute Lymphocytic Leukemia and Diabetes Mellitus. , 2014, Journal of radiology case reports.
[10] O. Abdel-Wahab,et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. , 2014, Blood.
[11] G. Cavalli,et al. Oncogene-Induced Senescence as a New Mechanism of Disease: The Paradigm of Erdheim–Chester Disease , 2014, Front. Immunol..
[12] M. Cazzola,et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study , 2013, Leukemia.
[13] P. Cluzel,et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. , 2013, Blood.
[14] C. Campochiaro,et al. The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases , 2013, Annals of the rheumatic diseases.
[15] M. Copin,et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. , 2012, Blood.
[16] R. Hoffman,et al. The renaissance of interferon therapy for the treatment of myeloid malignancies. , 2011, Blood.
[17] M. Griesshammer,et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[19] A. Tefferi,et al. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.
[20] A. Salar,et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients , 2009, British journal of haematology.
[21] M. Ferrarini,et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. , 2006, Arthritis and rheumatism.
[22] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[23] F. Sim,et al. Erdheim-Chester disease. , 2003, Orthopedics.
[24] C. Clerici,et al. Polycythemia vera treated with recombinant interferon‐alpha 2a: Evidence of a selective effect on the malignant clone , 1997, American journal of hematology.
[25] J. D. van der Walt,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.